美军使用THAM的经验
该回顾性描述性队列研究利用国防部创伤登记库数据,纳入2001年9月至2014年12月期间损伤严重度评分大于15的美军人员,比较接受THAM治疗的69例与未接受THAM治疗的4489例。THAM组平均ISS更高(33 vs 27,p<0.001),输注浓缩红细胞更多(37 vs 10,p<0.001),机械通气和ICU天数更长,出院存活率更低。单变量分析显示THAM与较低生存几率相关(OR 0.18,95%CI 0.11-0.31),但多变量分析控制混杂因素后,THAM使用与更差的生存几率无显著关联(OR 0.83,95%CI 0.21-3.24)。作者结论为在该战斗创伤人群中未能检测到THAM给药与更差的30天死亡率相关,需前瞻性研究验证其在危重伤员中的使用。
要点
- 在控制混杂因素后,THAM使用与30天生存几率无显著关联(OR 0.83,95%CI 0.21-3.24)。
- 接受THAM的伤员病情更重:平均ISS 33 vs 27(p<0.001),输注浓缩红细胞37 vs 10(p<0.001)。
- THAM组机械通气和ICU天数更长,出院存活率更低。
- 单变量分析中THAM与较低生存几率相关(OR 0.18,95%CI 0.11-0.31),但多变量分析后该关联消失。
- 作者认为需要前瞻性研究来验证THAM在危重伤员中的使用。
适用人群与场景
- 2001年9月至2014年12月期间纳入国防部创伤登记库的美军人员,损伤严重度评分大于15。
诊断标准与关键阈值
- 纳入标准:美军人员,损伤严重度评分大于15,2001年9月至2014年12月期间。
研究设计与关键结果
- 研究类型:回顾性描述性队列研究,数据来自国防部创伤登记库;共4558例符合纳入标准,其中69例接受THAM,4489例未接受。
- THAM组平均ISS 33 vs 非THAM组27(p<0.001),输注浓缩红细胞37 vs 10(p<0.001)。
- THAM组机械通气和ICU天数更长,出院存活率更低。
- 单变量分析:THAM与较低生存几率相关(OR 0.18,95%CI 0.11-0.31)。
- 多变量分析控制混杂因素后:THAM使用与更差的生存几率无显著关联(OR 0.83,95%CI 0.21-3.24)。
证据类型、等级与局限
- 证据类型:回顾性描述性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在战斗创伤人群中,控制混杂因素后未检测到THAM给药与更差的30天死亡率相关,但作者认为需要前瞻性研究验证其在危重伤员中的使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acidosis, a part of the lethal trauma triad, occurs frequently after major combat trauma. Tris-hydroxymethyl aminomethane (THAM) has been used to effectively treat acidosis in injured casualties. No research has been conducted assessing the safety of THAM in the military combat setting. We sought to describe the US military experience with THAM administration to battlefield injury subjects.
METHODS: We conducted a retrospective descriptive cohort study reviewing the trauma data from the Department of Defense Trauma Registry. US military personnel with an injury severity score greater than 15, between September 2001 and December 2014, were analyzed. Our primary outcome was the 30-day all-cause mortality among cohort treated with THAM versus those who were not. Differences between the cohort were examined using a student t-test (continuous variables), Wilcoxon Rank Sum test (ordinal variables), and chi-squared test (nominal variables).
RESULTS: 4558 subjects met the inclusion criteria. 69 received THAM and 4489 did not. Casualties receiving THAM had higher mean ISS scores (33 vs. 27, p < 0.001), and required significantly higher amounts of packed red blood cells (RBCs, 37 vs. 10, p < 0.001). THAM cohort had longer ventilator and intensive care unit (ICU) days with an overall lower survival to hospital discharge. On univariable analysis, THAM was associated with lower odds of survival (OR 0.18, 95% CI 0.11-0.31) but on multivariable analysis, when controlling for confounders, THAM use was not associated with a worse odds of survival (OR 0.83, 95% CI 0.21-3.24).
CONCLUSIONS: Within our combat trauma population, we were unable to detect worse 30 day mortality associated with THAM administration. Prospective investigations are needed to validate its use in critically injured combat casualties.
参考来源
- de Taboada G, Umar MA, Casmaer ML, et al. The US military experience with THAM. Am J Emerg Med. 2019. PMID: 31924438. doi:10.1016/j.ajem.2019.11.026
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。